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San Diego, California; and §Department of Informatics, University of Oslo, Oslo, NorwayABSTRACT Reduced conduction velocity (CV) in the myocardium is well known to increase the probability of arrhythmia and
can be caused by structural changes, reduced excitability of individual myocytes, or decreased electrical coupling in the tissue.
Recently, investigators have developed antiarrhythmic drugs that target the connections between individual myocytes with the
goal of restoring tissue CV, specifically through increasing gap-junction coupling. In a simple but qualitatively relevant mathe-
matical model, we show here that the introduction of a drug that improves intercellular conductance will indeed increase the
CV. However, conditions that would require such a drug, such as fibrotic remodeling, may also increase the load of fibroblasts.
Fibroblasts may couple to myocytes in much the same way as myocytes couple to each other, and therefore the use of such an
agent may also improve coupling between myocytes and fibroblasts. We present numerical examples illustrating that when the
load of coupled fibroblasts on myocytes is low or nonexistent, the drug works as expected, i.e., the drug increases CV. On the
other hand, when the fibroblast load is high, changes in CV are nonmonotonic, i.e., the CV first increases and then decreases
with an increase in dosage. The existence of coupled fibroblasts may therefore impair the effect of the drug, and under
unfortunate conditions may be proarrhythmic.INTRODUCTIONCardiac arrhythmia is characterized by disturbances in the
regular electrical signal that controls the orderly contraction
of cardiac muscle, resulting in a failure to adequately pump
blood to the body. Ventricular fibrillation, a particularly
dangerous arrhythmia wherein contraction of the heart
muscle is completely asynchronous, can result in death if
it is not treated within minutes. Decades of research have
thus been devoted to understanding arrhythmic origins.
One well-established mechanism of arrhythmia is the
reentrant circuit, a fast (tachy) arrhythmia that results in
inappropriately rapid and/or dyssynchronous contraction.
Induction of reentry is dependent on abnormally slowed
conduction and conduction block (1–3). In a typical induc-
tion scenario, an electrical activation wave could move more
slowly through some parts of the myocardium than others
due to an abnormally decreased conduction velocity (CV)
in those regions. Once the signal again reaches tissue with
normal conduction properties, it may travel backward
through this already recovered, excitable tissue (retrograde
propagation). The signal may finally enter the region with
decreased CV once again, repeating the pattern and initi-
ating a self-sustaining cycle, or reentrant circuit (4–7).
Furthermore, a variety of factors, including increased
heterogeneity in CV, may facilitate the breakup of a stable
reentrant circuit into unstable, dangerous fibrillatory activity
(8–11). As such, maintenance of normal conduction in the
myocardium, with minimal alteration of other tissue proper-
ties, is extremely desirable for cardioprotection (5,12).Submitted May 6, 2011, and accepted for publication November 22, 2011.
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0006-3495/12/01/0231/7 $2.00Cardiac CV is governed primarily by the rate of tissue
depolarization (i.e., the action potential upstroke velocity)
and the intercellular conductance (13). However, cardiac
drugs that might maintain CV by targeting upstroke
velocity are compounds that affect ion channels in the cell
membrane (i.e., sodium channels). Because cell membrane
ion channel distribution is highly heterogeneous among
cell types in the heart, as well as among individuals, alter-
ation of this function may affect diverse processes in unex-
pected, potentially unpredictable, and even dangerous ways
(14,15). Therefore, the notion of targeting the CV via the
connections between cardiomyocytes, or gap junctions, is
highly attractive.
A relatively new class of drugs, called antiarrhythmic
peptides (AAPs; e.g., rotigaptide (16,17) target the connexin
(Cx) proteins that comprise gap junctions, and are aimed at
improving communication between cells. However, an
important consideration is the fact that cardiac tissue is far
from homogeneous. Fibroblasts are the most numerous non-
myocyte cells in the heart. They outnumber myocytes by
least a factor of 2 and are responsible for creating and main-
taining the extracellular matrix that supports the myocar-
dium during normal function. However, in pathological
contexts wherein an AAP could potentially be used, such
as chronic fibrotic remodeling after ischemic injury (18),
fibroblasts may be present in increased numbers and with
altered function (i.e., activated as myofibroblasts). In partic-
ular, both homologous and heterologous cell coupling has
been postulated (19). Such intercellular coupling between
fibroblasts (F-F coupling) and/or between fibroblasts and
myocytes (F-M coupling) has been confirmed in vitro and
in in situ atria, and may exist in other tissues (20,21). Givendoi: 10.1016/j.bpj.2011.11.4015
232 Tveito et al.that F-F and F-M intercellular communication may be facil-
itated by the same Cxs as myocyte-myocyte (M-M) commu-
nication (22,21), gap-junctional coupling involving
fibroblasts may also be affected by any drug that is designed
to alter M-M intercellular conductances.
In this work, we consider a scenario in which the patho-
logical presence of fibroblasts in cardiac tissue can alter
the intended effect of a drug administered to maintain the
CV. Specifically, we present theoretical results that suggest
that fibrotic changes, particularly the presence of fibroblasts,
may impair the intended antiarrhythmic effect of a delivered
drug in a highly nonlinear fashion.METHODS
The model employed in this work considers a one-dimensional strand of
cardiomyocytes, each of which is electrically coupled to a specified number
of fibroblasts. F-M coupling is achieved as initially suggested by Jacquemet
and Henriquez (23). Further below, we also consider F-F coupling based on
a model introduced by Sachse et al. (24).Bidomain model
It is assumed that all fibroblasts associated with one cell are in the same
electrical state, and that the bidomain model (25) governs spatial coupling.
These considerations lead to the following system:
cmvt ¼ b1m ððsivxÞx þ ðsiuxÞxÞ  cmImðv; sÞ  Nf Ic; (1)
0 ¼ ðsivxÞ þ ððsi þ seÞuxÞ ; (2)x x
st ¼ Fðv; sÞ; rt ¼ Gðw; rÞ; (3)cf wt ¼ cf If þ Ic; (4)
where subscript t and x denote differentiation with respect to time and
space, respectively; v is the transmembrane potential of a myocyte; w isthe transmembrane potential of a fibroblast; u is the extracellular potential;
si and se are the intra- and extracellular conductivities, respectively; cm, cf
are the membrane capacitances for myocytes and fibroblasts, respectively;
bm is the myocyte density; Im, If denote the total ionic current densities of
myocytes and fibroblasts, respectively; Ic represents the electrical coupling
between one myocyte and its associated fibroblasts; and Nf denotes the
number of fibroblasts. The transmembrane potentials are assumed to be
given at time t ¼ 0, and all potentials are assumed to satisfy no-flux
boundary conditions. The ionic models of Maleckar et al. (26,27) are
used to specify s, F, r and G. The precise form of F and G can also be found
in the appendix of Tveito et al. (28). All model parameters are taken from
the original studies. We also investigated the effect of increasing the load of
fibroblasts on the solution as described previously (23,28).
The coupling current is assumed to take the form
Ic ¼ Gcðv wÞ; (5)
where Gc is the conductance between the myocyte and the fibroblasts.
In one spatial dimension, the bidomain model can always be written onthe form of the monodomain model. By integrating Eq. 2 and using the
boundary conditions, we find that the model can be written in the form
vt ¼ ðmvxÞx  Imðv; sÞ  hgcðv wÞ; (6)Biophysical Journal 102(2) 231–237st ¼ Fðv; sÞ; rt ¼ Gðw; rÞ; (7)wt ¼ If þ gcðv wÞ; (8)
wherem ¼ 1
bmcm
sise
si þ se (9)
and gc ¼ Gc=cf ; h ¼ Nf cf =cm. Here the intracellular conductivity is
given by
si ¼ spsc
sp þ sc; (10)
where sc is the intercellular conductivity regulated by gap junctions based
on Cxs, and s is the conductivity of the cytosol. By combining Eqs. 9 andp
10, we get
m ¼ 1
bmcm
scspse
sc

sp þ se
þ spse
: (11)
The drug in question is designed to improve conductivity through gap
junctions, and we assume that it will improve both M-M conductivity
and F-M conductance in the following way:
sdc ¼ scð1þ dÞ; (12)
gd ¼ g ð1þ dÞ; (13)c c
where d represents the strength of the drug. With these assumptions, we get
the diffusion coefficient
m ¼ 1
bmcm
ð1þ dÞscspse
ð1þ dÞsc

sp þ se
þ spse
; (14)
and for the coupling current, we get
Ic ¼ cf gcð1þ dÞðv wÞ: (15)
It follows from Eq. 14 that the diffusion coefficient depends on the
amount of drug d, the conductivity from myocyte to myocyte sc, the
conductivity of the cytosol-plasma sp, and the extracellular conductivity
se. Because the drug only affects the M-M conductivity, the efficacy of
the drug reaches an upper bound as the strength of the drug is increased.Introducing electrical diffusion between
fibroblasts
It has been suggested that fibroblasts also may form connections to neigh-
boring fibroblasts through gap junctions (29,30,24). To assess how such
coupling might affect the efficacy of an applied compound, we use the
model introduced by Sachse et al. (24). This model also permits integration
in space of one of the equations, reducing the model to a system of the form
vt ¼ ðmvvxÞx  ðmv;wwxÞx  Im  hgcðv wÞ; (16)
st ¼ Fðv; sÞ; rt ¼ Gðw; rÞ; (17)wt ¼ ðmw;vvxÞ þ

mf wx
  If þ gcðv wÞ; (18)x x
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mv ¼ 1
cmbm
sm

se þ sf

se þ sf þ sm; (19)
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FIGURE 1 Lower (A) and higher (B) regimes of CV as a function of
applied drug for fibroblast loads Nf ¼ 0–5 (black through magenta traces,
as shown in legend), in the absence of F-F coupling.mw ¼
cf bf se þ sf þ sm
; (21)
and
mw;v ¼ 1
cf bf
smsf
se þ sf þ sm; (22)
where bm and bf are the myocyte and fibroblasts per volume, respec-
tively; sf denotes the conductivity between fibroblasts as facilitated by
gap junctions (F-F coupling; see Table 1 for values); and sm denotes the
conductivity between myocytes.
Following Sachse et al. (24), we use bm ¼ 0:8=ðVm þ Nf Vf Þ and
bf ¼ Nf bm, where Vm and Vf are the cell volumes of myocytes and fibro-
blasts, respectively. The drug effect on sm and sf is modeled in the same
way as described for si in the ‘‘Bidomain model’’ section above.Introducing multiple regimes of CV
To consider the effect of an AAP in the context of both a relatively normal
and a reduced CV (as may occur in vitro, or due to gap-junctional uncou-
pling), we included two regimes of CV: one with conductivities as used
by Sachse et al. (24) (see Table 1), and one with a regime of relatively lower
velocities obtained by reducing the default conductivities to 30% of their
original values.Parameters and numerical solution
The system was solved by means of operator splitting. The partial differen-
tial equations were discretized with finite-difference discretization in space
using Dx ¼ 0.05mm, and ordinary differential equations were solved with
the use of a second-order Rush-Larsen method (31).RESULTS
We first sought to investigate how CV changes with an
increasing amount of drug for different fibroblast loads in
the absence of F-F coupling. In Fig. 1 we show two regimes
of CVs (lower (A, top) and higher (B, bottom)) as a function
of drug concentration for a variety of applied fibroblast
loads. When the fibroblast load is zero (Nf ¼ 0, blackTABLE 1 Parameters taken from previous studies (23,24,26)
Parameter Value Parameter Value
se 3.75 mS/cm cm 50 pF
sp 9.38 mS/cm cf 6.3 pF
sc 9.38 mS/cm Vm 16 pL
sf 10 mS/cm Vf 0.268 pL
gc 0.1/ms gNa 1.8 pL/straces), the applied compound increases the CV, an effect
that also holds for low fibroblast load for both velocity
regimes (Nf ¼ 1, blue traces). However, as the load of fibro-
blasts increases, the effect of the drug is altered for both
velocity regimes, and more severely so in the case of
reduced CV (A, top). In this case, increasing the amount
of applied AAP in the presence of a fibroblast load of
Nf ¼2 (A, green trace) has very little effect on CV, and
increasing Nf to 3 (A, red trace) actually leads to a reduced
CV with increasing amount of compound, and conduction
block for a sufficiently high amount of the applied drug
(red trace; Nf ¼ 3, d > 0.15). Increasing the fibroblast
load beyond this point in the context of an already compro-
mised CV results in conduction block in the model for all
conditions (A, Nf ¼ 3, 4, or 5; not shown). In the case of
higher CV (B, bottom), an increase in fibroblast loading
up to Nf ¼ 3 (blue to red traces) results in an increase in
CV with an increasing amount of applied compound.
However, further increasing the fibroblast load in this
velocity regime (Nf ¼ 4 and 5; brown and magenta traces,
respectively) results in a progressive decrease in CV with
applied AAP, eventually leading to conduction block in
the most extreme case of CV reduction (magenta trace;
Nf ¼ 5, d > 0.21).
In Fig. 2 we illustrate the effect of perturbing essential
parameters of the model (6–8) in the case of normal (upper
panel, Nf ¼ 5) and reduced (lower panel, Nf ¼ 3) CVs. We
observe that perturbing sp, sc, gc and gNa by510% indeed
alters the CV, but the effect of introducing the drug remains
unaltered in 15 of 16 cases. The exception is the perturba-
tion of gNa in the normal CV regime, where in the þ10%
case we observe that the drug improves CV, whereas in
the case of 10%, the drug impairs CV.Biophysical Journal 102(2) 231–237
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FIGURE 2 Dependence of lower (A) and higher (B) regimes of CVon the
applied drug for a variety of values for parameters sp,sc,gc, and gNa.
Default values are shown as 100% (black traces). In A (Nf ¼ 5) and B
(Nf ¼ 3), sp, sc, gc, and gNa are varied510%.
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FIGURE 3 Lower (A) and higher (B) regimes of conduction velocity
(CV) as a function of applied drug for fibroblast loads Nf ¼ 1–6 (blue
through gold traces, as shown in legend), for a high value of F-F coupling
(10 mS/cm for 100% volume ratio).
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FIGURE 4 Lower (A) and higher (B) regimes of CV as a function of
applied drug for F-F coupling levels sf ¼ 0–10 (dashed circle through
square solid lines, as shown in legend), for a nominal fibroblast load
(Nf ¼ 4).
234 Tveito et al.Fig. 3 shows the change in CV with an increasing amount
of drug for different fibroblast loads when we account for
coupling between fibroblasts (F-F). In a regime of reduced
CV, accounting for the possibility of homologous F-F gap
junctions results in increased CV with an increasing amount
of the applied drug (Nf ¼ 1–3; the maximum CV in Fig. 3 A
is 22 cm/s as compared with 17 cm/s in Fig. 1), and conduc-
tion does not block until a higher overall fibroblast load is
applied to the tissue (Nf ¼ 4, as compared with Nf ¼ 3 in
Fig. 1). In a relatively normal regime of CV (B, bottom),
accounting for F-F coupling in the tissue suggests that
conduction block would not occur as readily (compare
magenta traces, Nf ¼ 5, in Figs. 1 B and 3). In addition,
the inclusion of F-F coupling here results in a consistently
increasing CV with increased applied AAP, except in the
case of very high fibroblast loading (yellow trace, Nf ¼ 6).
These effects may not be constant with the amount of
assumed coupling between fibroblasts, however, and a range
of diffusion between fibroblasts (0–10 mS/cm) is investi-
gated in Fig. 4 for a constant fibroblast load of Nf ¼ 4.
Here, results are vastly different for the reduced (A, top)
and normal (B, bottom) CV regimes. For the already reduced
CV regime (top), the lowest values of F-F diffusion, 0 and
2 mS/cm (dashed circle and solid circle traces, respec-
tively), are not sufficient to overcome the conduction block
for this fibroblast load, even in the absence of an applied
AAP, and are not shown. Otherwise, CV consistently
decreases in this regime for this fibroblast load (Nf ¼ 4)Biophysical Journal 102(2) 231–237with an increasing amount of drug, eventually ending in
conduction block above a certain efficacy of AAP (all traces
shown). Interestingly, however, increasing the F-F conduc-
tance from 4 to 10 mS/cm (dashed Xs through solid square
traces in Fig. 4 A) actually increases the baseline CV in the
absence of the applied compound (d¼ 0). Whereas the same
is actually true for a normal (higher) regime of CVunder the
same fibroblast load (Fig. 4 B, bottom, d¼ 0), increasing the
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FIGURE 6 Two sets of auxiliary conductivities as a function of fibroblast
load for three levels of applied drug (d ¼ 0, 0.15. 0.30; cyan, gray, and
orange lines, respectively, as shown in legend).
Proarrhythmic Potential of Drugs 235amount of applied drug slightly increases rather than
decreases CV for all values of F-F conductance.
As shown in Figs. 1–4, CV in both reduced and normal
regimes depends on the fibroblast load Nf and the amount
of applied drug d in a highly nonlinear fashion. In Figs. 5
and 6, we examine how the auxiliary conductivities mv,
mw, mv,w, and mw,v (see Methods section) that determine
the resultant CV in the simulated tissue depend on these
variables. As shown in Fig. 5, mv (solid) and mvw (dashed)
increase with an increasing amount of applied drug, are
comparable in magnitude, and have a rather weak depen-
dency on fibroblast load (A). The auxiliary conductivities
mw (solid) and mwv (dashed), however, strongly depend on
the fibroblast load but reveal less dependence on the amount
of applied drug (B). When the transpose dependence of the
auxiliary conductivities with respect to the applied drug is
examined (Fig. 6), it reveals increases in mv and mvw with
the amount of drug, with higher fibroblast load (Nf ¼ 1, 3,
5; blue, red, and magenta traces, respectively) resulting in
higher conductivities (A). Fig. 6 B reveals very little depen-
dence on howmw (solid) andmwv vary with the applied drug;
rather, as in Fig. 5 B, there is a very high dependence on
fibroblast load (Nf ¼ 1, 3, 5; blue, red, and magenta traces,
respectively).DISCUSSION
In this work we examined the effects of drugs designed to
enhance gap-junctional coupling on cardiac CV given the
presence of fibrotic changes, and particularly coupled fibro-
blasts, in simulated cardiac tissue. The central finding of this0 2 4 61
1.2
1.4
1.6
1.8
0 2 4 60
5
10
15
20
Nf
au
xi
lia
ry
 c
on
du
ct
iv
ity
 (c
m
2 /
s)
mv
mv,w
mw
mw,v
0
0.15
0.3
0
0.15
0.3
0
0.15
0.3
0
0.15
0.3
A
B
FIGURE 5 Two sets of auxiliary conductivities as a function of applied
drug for three fibroblast loads (Nf ¼ 1,3,5; blue, red, and magenta lines,
respectively, as shown in legend).study is that any drug that is designed to enhance gap-junc-
tional coupling in cardiac tissue may have diverse effects on
cardiac CV depending on the presence of fibroblasts that are
capable of forming functional gap junctions with myocytes
and with each other. This observation holds for a variety of
model parameters. Previous work has shown that, in the
absence of fibroblasts, CV increases monotonically with
gap junctional coupling (32,17), a finding that is corrobo-
rated by the results we obtained in simulations in which
rotigaptide was applied in the absence of fibroblasts (see
Fig. 1, black traces). Such an increase in wavefront velocity
on conduction-impaired zones could indeed be expected to
decrease the probability of reentrant arrhythmias by limiting
the incidence of conduction block, and experiments have
shown that such peptides are antiarrhythmic in reentrant
and reperfusion ventricular (33,34) and atrial dilatation
(35,36) arrhythmias.
However, in this study, we found that in the presence of
fibroblasts, increasing the fibroblast load on myocardium
(either by increasing the fibroblast density in tissue or by
altering the gap-junctional coupling conductance of fibro-
blasts in connection to myocytes) resulted in a biphasic
effect on CV (Fig. 1), as previously observed in both exper-
imental and computational studies (20,37). A progressive
increase in fibroblast density decreased the CV in tissue
(Fig. 1). However, when the effects of rotigaptide, which
was designed to restore gap-junctional conductance and
effective CV, were simulated for diverse levels of fibroblast
loading, the response was highly nonlinear. A lower range of
fibroblast loading (Nf ¼ 1, 2, 3) on tissue resulted in slightly
increased CV with increasing drug dosage (Fig. 1 B,
blue, green, and red traces). However, for higher levels ofBiophysical Journal 102(2) 231–237
236 Tveito et al.fibroblast loading (Nf ¼ 4, 5), CV actually decreased
with increasing drug concentration (Fig. 1 B, brown and
magenta traces), further compromising an already impaired
conduction and potentially creating a substrate prone to
conduction block and/or increased vulnerability to reentrant
arrhythmias.
An important consideration in this work is conductivity
remodeling, including potential coupling between the fibro-
blasts themselves (29,30,38), which may affect tissue
loading and velocities of wavefront conduction. Figs. 3
and 4 illustrate the effects of F-F coupling on CV. In general,
CV increases with interfibroblast coupling in the absence of
applied drug (d ¼ 0). It is possible that some decreases in
CV with an increased amount of applied antiarrhythmic
compound (e.g., as seen with increasing fibroblast load in
simulations that do not take interfibroblast coupling into
account) can be mitigated in tissues that possess homocellu-
lar junctions between fibroblasts. At the very least, it is
essential to acknowledge that nexus junctions between
both homologous and heterogeneous cell types may exist
during remodeling, which may result in heterogeneous
tissue conductivities that can be altered in unpredictable
ways during AAP application.
Despite the wealth of experimental information that has
become available in recent years, there is still a dearth of
published data pertinent to several parameters used in the
model presented here. In particular, the ratio of sp to sc
and the values of sf and gc presented difficulties due to an
incomplete or nonexistent experimental characterization.
We attempted to choose reasonable values based on the
simplest assumption (i.e., the ratio of sp to sc) or previously
published work (i.e., sf and gc) (29,30,24). Moreover, our
observations seem to be robust under perturbations of the
data. However, future experimental findings that allow
a more informed parameterization may increase the physio-
logical relevance of our model and confidence in the results.
In addition, it should be noted that although our simple
model provides qualitatively relevant results with respect
to measurements in human atrial cells and tissues, it models
gap junctions as a standard cell-cell connection that is not
specified in terms of Cxs, the individual proteins that
comprise a single gap junction. In myocardium, cell-cell
communication may be organized through gap junctions
comprised of two identical (homotypic) or two different
(heterotypic) hemichannels that in turn are comprised of
one type of Cx (homomeric) or many Cx isoforms (hetero-
meric). Each Cx may apportion distinct conductance,
permeability, selectivity, and gating properties to the gap
junction (39). Four Cx isoforms (mCx30.2/hCx31.9, Cx40,
Cx43, and Cx45 (40) have been identified in the heart,
and both Cx43 and Cx40 are abundant in human atrial
tissue. Potential effects on gap junctions comprised of
specific Cxs could very well be relevant and should be taken
into account in future studies designed to assess the effects
of specific AAPs.Biophysical Journal 102(2) 231–237Further, a brief comment should be made regarding the
controversial nature of F-M coupling. Although in vitro
and in situ evidence of F-M coupling has been reported
(20,21), the existence of F-M coupling in in vivo tissue
has been called into question because this has not yet been
measured (41). Attempts to quantify the fibroblast load on
myocytes by in vitro experiments (21) proved to be difficult
to translate and resulted in an uncertain range. Despite this
limitation, in this study we applied a range of fibroblast
loads on myocytes in an exploratory manner (thus including
relatively high values) based on the experimental informa-
tion available. F-F connections are somewhat less contro-
versial and have been seen in several tissues in addition to
myocardium (42,43), but little more in situ or in vivo
evidence is available regarding their existence in cardiac
tissue. Finally, fibroblasts and myofibroblasts are phenotyp-
ically divergent cell types (41), and one or both types may
be involved in the myocardium at various stages of damage
and healing; however, we did not make a distinction
between these two cell types in this study. Advances in
experimental approximation methods will enable investiga-
tors to elucidate electrotonic coupling in these diverse cell
types, gain insight into probable tissue- and organ-level
effects of AAPs, and conduct more-advanced and pertinent
simulations of AAP therapies.
In this first, to our knowledge, study designed to examine
the gamut of effects that AAPs can elicit in tissue given suffi-
cient efficacy, we neglected voltage and ligand gating of the
gap junctions themselves, which indubitably could apportion
relevant effects on the CV in fibrosis-compromised tissue.
A final comment may be madewith regard to the observed
range of increase in gap-junctional conductance and its rela-
tion to our experimental findings. In this study, we applied an
increase in conductance of up to 20% in accordance with
recent experiments (17). However, the future development
of AAPs may reveal a very different range of efficacies on
diverse Cxs, which could potentially alter the results dramat-
ically and would require further investigation.
CONCLUSIONS
For the theoretical model presented here, we conclude that
in the absence of fibroblasts, a drug that improves gap-junc-
tional coupling may increase the CVand thereby reduce the
risk of conduction abnormalities, unidirectional block, and
the formation of reentrant arrhythmias. On the other hand,
if there is a significant load of fibroblasts on the myocyte,
the intended effect of the drug may be altered, leading in
extreme cases to a reduced CV. This certainly implies
a possible risk for the use of such pharmacological agents
in already highly heterogeneous tissue in terms of substrate
formation for arrhythmia generation and maintenance.
This research was supported by a Center of Excellence grant from the
Research Council of Norway to the Center for Biomedical Computing at
the Simula Research Laboratory.
Proarrhythmic Potential of Drugs 237REFERENCES
1. Mines, G. R. 1913. On dynamic equilibrium in the heart. J. Physiol.
46:349–383.
2. Mines, G. R. 1914. On circulating excitations in heart muscle and their
possible relation to tachycardia and fibrillation. Trans. R. Soc. Can.
4:43–52.
3. Durrer, D., K. I. Lie, ., R. M. Schuilenburg. 1978. Mechanisms of
tachyarrhythmias, past and present. Eur. J. Cardiol. 8:281–297.
4. Wit, A. L., and M. R. Rosen. 1983. Pathophysiologic mechanisms of
cardiac arrhythmias. Am. Heart J. 106:798–811.
5. Janse, M. J., and C. N. D’Alnoncourt. 1987. Reflections on reentry and
focal activity. Am. J. Cardiol. 60:21F–26F.
6. Pogwizd, S. M., R. H. Hoyt,., M. E. Cain. 1992. Reentrant and focal
mechanisms underlying ventricular tachycardia in the human heart.
Circulation. 86:1872–1887.
7. Boersma, L., J. Brugada, ., M. Allessie. 1993. Entrainment of reen-
trant ventricular tachycardia in anisotropic rings of rabbit myocardium.
Mechanisms of termination, changes in morphology, and acceleration.
Circulation. 88:1852–1865.
8. Qu, Z., F. Xie, ., J. N. Weiss. 2000. Origins of spiral wave meander
and breakup in a two-dimensional cardiac tissue model. Ann. Biomed.
Eng. 28:755–771.
9. Panfilov, A. V. 2002. Spiral breakup in an array of coupled cells: the
role of the intercellular conductance. Phys. Rev. Lett. 88:118101.
10. Weiss, J. N., P. S. Chen, ., A. Garfinkel. 2002. Electrical restitution
and cardiac fibrillation. J. Cardiovasc. Electrophysiol. 13:292–295.
11. Plank, G., L. J. Leon,., E. J. Vigmond. 2005. Defibrillation depends
on conductivity fluctuations and the degree of disorganization in
reentry patterns. J. Cardiovasc. Electrophysiol. 16:205–216.
12. Wit, A. L., and J. Coromilas. 1993. Role of alterations in refractoriness
and conduction in the genesis of reentrant arrhythmias. Implications for
antiarrhythmic effects of class III drugs. Am. J. Cardiol. 72:3F–12F.
13. Saffitz, J. E., H. L. Kanter,., E. C. Beyer. 1994. Tissue-specific deter-
minants of anisotropic conduction velocity in canine atrial and ventric-
ular myocardium. Circ. Res. 74:1065–1070.
14. Greene, H. L., D. M. Roden, ., R. W. Henthorn. 1992. The cardiac
arrhythmia suppression trial: first CAST.then CAST-II. J. Am. Coll.
Cardiol. 19:894–898.
15. Pratt, C. 1998. Clinical implications of the survival with oral d-sotalol
(SWORD) trial: an investigation of patients with left ventricular
dysfunction after myocardial infarction. Card. Electrophysiol. Rev.
2:28–29. 10.1023/A:1009982121597.
16. Haugan, K., and J. S. Petersen. 2007. Gap junction-modifying antiar-
rhythmic peptides: therapeutic potential in atrial fibrillation. Drugs
Future. 32:245–260.
17. Lin,X., C.Zemlin,., R.D.Veenstra. 2008.Enhancement of ventricular
gap-junction coupling by rotigaptide. Cardiovasc. Res. 79:416–426.
18. Ren, Y., C. T. Zhang,., L. Wang. 2006. [The effects of antiarrhythmic
peptide AAP10 on ventricular arrhythmias in rabbits with healed myo-
cardial infarction]. Zhonghua Xin Xue Guan Bing Za Zhi. 34:825–828.
19. Rohr, S. 2009. Myofibroblasts in diseased hearts: new players in
cardiac arrhythmias? Heart Rhythm. 6:848–856.
20. Miragoli, M., G. Gaudesius, and S. Rohr. 2006. Electrotonic modula-
tion of cardiac impulse conduction by myofibroblasts. Circ. Res.
98:801–810.
21. Camelliti, P., C. R. Green, ., P. Kohl. 2004. Fibroblast network in
rabbit sinoatrial node: structural and functional identification of homo-
geneous and heterogeneous cell coupling. Circ. Res. 94:828–835.
22. Gaudesius, G., M. Miragoli, ., S. Rohr. 2003. Coupling of cardiac
electrical activity over extended distances by fibroblasts of cardiac
origin. Circ. Res. 93:421–428.
23. Jacquemet, V., and C. S. Henriquez. 2007. Modelling cardiac fibro-
blasts: interactions with myocytes and their impact on impulse propa-
gation. Europace. 9 (Suppl 6):vi29–vi37.24. Sachse, F. B., A. P. Moreno,., J. A. Abildskov. 2009. A model of elec-
trical conduction in cardiac tissue including fibroblasts. Ann. Biomed.
Eng. 37:874–889.
25. Keener, J., and J. Sneyd. 2009. Mathematical Physiology. Springer,
New York.
26. Maleckar, M. M., J. L. Greenstein, ., N. A. Trayanova. 2009. Kþ
current changes account for the rate dependence of the action potential
in the human atrial myocyte. Am. J. Physiol. Heart Circ. Physiol.
297:H1398–H1410.
27. Maleckar, M. M., J. L. Greenstein,., N. A. Trayanova. 2009. Electro-
tonic coupling between human atrial myocytes and fibroblasts alters
myocyte excitability and repolarization. Biophys. J. 97:2179–2190.
28. Tveito, A., G. T. Lines,., M. M. Maleckar. 2011. Existence of exci-
tation waves for a collection of cardiomyocytes electrically coupled to
fibroblasts. Math. Biosci. 230:79–86.
29. Rook, M. B., H. J. Jongsma, and B. de Jonge. 1989. Single channel
currents of homo- and heterologous gap junctions between cardiac
fibroblasts and myocytes. Pflu¨gers Arch. 414:95–98.
30. Rook, M. B., A. C. van Ginneken,., H. J. Jongsma. 1992. Differences
in gap junction channels between cardiac myocytes, fibroblasts, and
heterologous pairs. Am. J. Physiol. 263:C959–C977.
31. Sundnes, J., R. Artebrant, ., A. Tveito. 2009. A second-order algo-
rithm for solving dynamic cell membrane equations. IEEE Trans. Bio-
med. Eng. 56:2546–2548.
32. Shaw, R. M., and Y. Rudy. 1997. Ionic mechanisms of propagation in
cardiac tissue. Roles of the sodium and L-type calcium currents during
reduced excitability and decreased gap junction coupling. Circ. Res.
81:727–741.
33. Xing, D., A.-L. Kjølbye,., J. B. Martins. 2003. ZP123 increases gap
junctional conductance and prevents reentrant ventricular tachycardia
during myocardial ischemia in open chest dogs. J. Cardiovasc. Electro-
physiol. 14:510–520.
34. Hennan, J. K., R. E. Swillo, ., D. L. Crandall. 2006. Rotigaptide
(ZP123) prevents spontaneous ventricular arrhythmias and reduces
infarct size during myocardial ischemia/reperfusion injury in open-
chest dogs. J. Pharmacol. Exp. Ther. 317:236–243.
35. Guerra, J. M., T. H. Everett, 4th, ., J. E. Olgin. 2006. Effects of the
gap junction modifier rotigaptide (ZP123) on atrial conduction and
vulnerability to atrial fibrillation. Circulation. 114:110–118.
36. Shiroshita-Takeshita, A., M. Sakabe,., S. Nattel. 2007. Model-depen-
dent effects of the gap junction conduction-enhancing antiarrhythmic
peptide rotigaptide (ZP123) on experimental atrial fibrillation in
dogs. Circulation. 115:310–318.
37. Jacquemet, V., and C. S. Henriquez. 2008. Loading effect of fibroblast-
myocyte coupling on resting potential, impulse propagation, and repo-
larization: insights from a microstructure model. Am. J. Physiol. Heart
Circ. Physiol. 294:H2040–H2052.
38. Kohl, P., A. G. Kamkin, ., D. Noble. 1994. Mechanosensitive fibro-
blasts in the sino-atrial node region of rat heart: interaction with cardi-
omyocytes and possible role. Exp. Physiol. 79:943–956.
39. Rackauskas, M., V. K. Verselis, and F. F. Bukauskas. 2007. Perme-
ability of homotypic and heterotypic gap junction channels formed
of cardiac connexins mCx30.2, Cx40, Cx43, and Cx45. Am. J. Physiol.
Heart Circ. Physiol. 293:H1729–H1736.
40. Lin, X., J. Gemel, ., R. D. Veenstra. 2010. Connexin40 and con-
nexin43 determine gating properties of atrial gap junction channels.
J. Mol. Cell. Cardiol. 48:238–245.
41. Duffy, H. S. 2011. Fibroblasts, myofibroblasts, and fibrosis: fact,
fiction, and the future. J. Cardiovasc. Pharmacol. 57:373–375.
42. Salomon, D., J. H. Saurat, and P. Meda. 1988. Cell-to-cell communica-
tion within intact human skin. J. Clin. Invest. 82:248–254.
43. Trovato-Salinaro, A., E. Trovato-Salinaro, ., C. Vancheri. 2006.
Altered intercellular communication in lung fibroblast cultures from
patients with idiopathic pulmonary fibrosis. Respir. Res. 7:122.Biophysical Journal 102(2) 231–237
